Background and purpose: Stomatitis or oral inflammation is one of the common complications in patients undergoing chemotherapy, which causes pain, discomfort, infection and long-term hospitalization. The only way to prevent this condition is to use a suitable mouthwash and maintain oral hygiene. The purpose of this study is to investigate the effect of Cordia myxa mouthwash on preventing stomatitis in patients undergoing chemotherapy. Method: This study will be a double-blind, single-center randomized controlled clinical trial focusing on 60 patients undergoing chemotherapy. The samples will be randomly divided into intervention and control groups. In addition to receiving the routine betadine mouthwash, participants in the intervention group will receive a solution of 30 drops of 5% Cordia myxa formulation in 20 cc of water, and they will be asked to put the solution in their mouth, swirl it in their mouth for a minute and then spit it out. In the control group, in addition to betadine mouthwash, sterile water placebo (having the same taste and smell) will be used. Patients will brush their mouths with a soft toothbrush and the same toothpaste 3 times a day after breakfast, lunch, and dinner followed by mouthwash use for 14 days. Data will be collected using a demographic information questionnaire and the oral stomatitis severity checklist. The data will be analyzed based on statistical tests using SPSS version 22. Discussion: This study is expected to shed light on the effectiveness of Cordia myxa mouthwash in improving the severity of stomatitis among leukemia patients. To the best of our knowledge, no valid scientific research has so far been conducted on this very topic. If this intervention proves effective in improving access and adherence to treatment, it would be a step forward in addressing a chronic health problem that is common among leukemia patients undergoing chemotherapy. Given its natural essence and the fact that it is not associated with any complications, the Cordia myxa mouthwash can be used safely alongside the main treatment to prevent and reduce the severity of mouth ulcers caused by chemotherapy.
Background: One of the common treatments for cancer is chemotherapy that is usually done by intravenous injection. Central catheters and portholes are used for the intravenous administration of chemotherapy drugs through peripheral vessels. Objectives: This study aimed to compare the caring outcomes of the two methods of drug injection through the peripheral vessels and ports in patients undergoing chemotherapy. Methods: In this descriptive study, 68 cancer patients admitted to the Hematology and Oncology Wards of Shahid Baghaei Hospital 2 in Ahwaz during three months were evaluated in two groups of 34 patients receiving chemotherapy (one group via ports and one group via peripheral blood vessels). Data were collected by a questionnaire consisting of two parts: demographic information (sex, age, and type of disease) and information about the patient's condition (drug injection method, serum, and catheter number), and an observational checklist including inflammation rate, drug extravasation, limitation of patient movement, medical expenses, and patient satisfaction. Data were analyzed using SPSS version 24 software. Results: According to the results of the study, the two groups were compared in terms of inflammation (P = 0.0001, T = 4.908), drug extravasation (P = 0.0001, T = 3.872), movement limitation P = 0.000, T = 4.922) the cost of treatment (P = 0.0001, χ2 = 56.973, P = 0.000, and patient satisfaction (P = 0.0001, T = -23.66). Conclusions: Performing chemotherapy through the port has fewer side effects and brings more comfort to the patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.